-
Real-World Treatment Switch Rates, and Healthcare Costs of Botulinum Toxin Type A Among Patients with Cervical Dystonia in the USA: A Retrospective Claims Analysis
-
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors
-
Botulinum Toxin A in Poststroke Oromandibular Dystonia: Case Reports
-
Clinical Characteristics of Over‐The‐Counter Drug Misusers in Psychiatric Practice in Japan: Comparison by Type of Drug Misused for the First Time
-
Treatment of patients with comorbid pain syndromes: an effective and safe approach
-
Clinical Characteristics, Treatment Patterns, and Drug-Resistant Epilepsy Among Emirati Adults with Epilepsy
-
Spinal Cord CELF4 in Chronic Constriction Injury-Induced Neuropathic Pain: Association with TRPV1 and COX-2 Expression
-
Chronic pain and mental disorders: a frequent comorbidity requiring a new comprehensive approach
-
A comprehensive approach involving a psychiatrist in the management of patients with chronic non-specific neck and back pain who also have anxiety and depressive disorders
-
Treatment Preferences for Subcutaneous Immunoglobulin Among Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment
-
Empowering Patients, Preventing Strokes: Knowledge of Risk Factors and Associated Factors, Prevention Strategies, and Treatment Awareness Among Chronic Disease Patients in Southern Ethiopia
-
Characteristics and long‐term outcomes of children with confirmed focal cortical dysplasia type 1 after epilepsy surgery: A population‐based study
-
Clozapine as an Off-Label Treatment for Severe and Treatment-Resistant (Auto-)Aggressive Behavior in a 40-Year-Old Patient With Mild Intellecutal Disability and Borderline Personality Disorder
-
Real‐world effectiveness of cenobamate in drug‐resistant and ultra‐refractory epilepsy: A multicenter study
-
αT-catenin in restricted brain cell types and its potential connection to autism
-
A first in disease trial of the safety, tolerability, and anti‐seizure effects of ES‐481 in drug‐resistant epilepsy
-
A Case Report and Literature Review of Charcot-Marie-Tooth Disease Type 2F in a Family
-
The frequency and prognostic significance of ‘new’ behavioural signs in patients with chronic impaired consciousness
-
Functional gradient variations in different neuroticism levels and its correlation with cell type-specific transcriptional signatures
-
Effectiveness of adjunctive low‐dose clobazam in adults with focal drug‐resistant epilepsy and incomplete response to cenobamate: A real‐world study
-
Voice treatment in Parkinson’s disease: patient perspectives
-
Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment‐Resistant Depression: A Qualitative Study
-
“Dream Insertion”: A Case Report of a Novel Psychotic Symptom in a Male Inpatient With Treatment Resistant Schizophrenia
-
Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial
